Oumédaly Reman - Concepedia

Author

Oumédaly Reman

Centre Hospitalier Universitaire de Caen Normandie

Also Known As

Julie Bonhomme, O Reman, O. Reman, Oumedaly Reman, Oumédaly Reman, Oumédaly Reman, Reman Oumedaly, Stéphane de Botton, T de Revel

108

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Caen Normandie Hôpital Saint-Louis Sorbonne Université Assistance Publique – Hôpitaux de Paris Hôpital Edouard Herriot

About

Oumédaly Reman is an author at Centre Hospitalier Universitaire de Caen Normandie specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	33	3.1K
2	Health Sciences	15	18	1.3K
3	Blood Transplantation	2	2	54
4	Cellular Therapies	2	2	90
5	Cell Biology	1	1	17

Oumédaly Reman

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Sylvie Castaigné, Cécile Pautas, Christine Terré, The Lancet Hematological MalignancyOncologyGemtuzumab OzogamicinMixed-phenotype Acute LeukemiaAdult Patients	2012	975
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial Xavier Thomas, Jean-Michel Boiron, Françoise Huguet, Journal of Clinical Oncology	2004	541
Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease Christophe Fermé, Houchingue Eghbali, J.H. Meerwaldt, New England Journal of Medicine	2007	444
Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial John Raemaekers, Marc André, Massimo Federico, Journal of Clinical Oncology	2014	381
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study Adrienne de Labarthe, Philippe Rousselot, Françoise Huguet‐Rigal, Blood	2006	343
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget, Blood	2016	318
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group A.-L. Taksin, Ollivier Legrand, Emmanuel Raffoux, Leukemia Hematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematologyMyeloid Neoplasia	2006	282
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial Emmanuelle Tavernier, JM Boiron, Françoise Huguet, Leukemia Hematological MalignancyLymphoid NeoplasiaLala-94 TrialOncologyMixed-phenotype Acute Leukemia	2007	254
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study Vahid Asnafi, Agnès Buzyn, Sandrine Le Noir, Blood	2008	237
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy Hartmut Döhner, Michael Lübbert, Walter Fiedler, Blood	2014	227

Page 1